-
41.发明申请公开(公告)号：US20220298491A1
公开(公告)日：2022-09-22
申请号：US17696763
申请日：2022-03-16
摘要： Disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.
-
公开(公告)号：US20220193170A1
公开(公告)日：2022-06-23
申请号：US17505394
申请日：2021-10-19
IPC分类号： A61K36/71 , A61K31/09 , A61K31/26 , A61K31/352 , A61K31/122 , A61P25/28 , A61K31/785
摘要： Disclosed are compositions of matter, protocols, and treatment means for preventing and/or reversing multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or Nigella sativa, and/or sulforaphane, and/or epigallocatechin-3-gallate (EGCG) are provided.
-
公开(公告)号：US20220175701A1
公开(公告)日：2022-06-09
申请号：US17545301
申请日：2021-12-08
IPC分类号： A61K31/138 , A61K36/235 , A61K36/82 , A61K31/09 , A61K31/095 , A61K45/06
摘要： Disclosed are means and methods of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or Nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiment's nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.
-
公开(公告)号：US20220160809A1
公开(公告)日：2022-05-26
申请号：US17534292
申请日：2021-11-23
发明人： Thomas Ichim , Timothy G. Dixon , Famela Ramos , Wais Kaihani
IPC分类号： A61K36/82 , A61K31/155 , A61K36/45 , A61K36/31 , A61K36/71 , A61K31/352 , A61K31/122 , A61K31/09 , A61K31/26 , A61P37/04
摘要： Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.
-
公开(公告)号：US20220125852A1
公开(公告)日：2022-04-28
申请号：US17512496
申请日：2021-10-27
IPC分类号： A61K35/28
摘要： Disclosed are therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions. In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is accomplished by administration of stem cells and/or endothelial cells.
-
公开(公告)号：US20220096542A1
公开(公告)日：2022-03-31
申请号：US17364646
申请日：2021-06-30
IPC分类号： A61K35/15
摘要： Stimulation of immunity would be beneficial in various chronic conditions such as viral infections and neoplasia. Autologous dendritic cell therapy has been widely described in the immunotherapy literature and has been approved by the FDA for treatment of prostate cancer. Unfortunately, the need to generate individual doses is costly and limited by ability of the patients to have sufficient starting cell numbers available to generate sufficient dendritic cells. Here we describe the process of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions that would benefit from NK activation such as cancer and COVID-19.
-
公开(公告)号：US20170020930A1
公开(公告)日：2017-01-26
申请号：US15215344
申请日：2016-07-20
发明人： Thomas Ichim , Timothy G. Dixon
IPC分类号： A61K35/744 , A61K35/745 , A23L33/135 , A61K35/747
CPC分类号： A61K35/744 , A23L33/135 , A61K35/745 , A61K35/747 , A61K2035/115
摘要： Methods for the treatment of pregnancy complications through immune modulation are disclosed. Also disclosed are probiotic compositions capable of inducing an anti-inflammatory immune response in a subject. The probiotic composition may include one or more of Streptococcus thermophiles, Lactobacillus reuteri, Bifidobacterium bifidium, Lactobacillus acidophilus, and Lactobacillus casei.
摘要翻译： 公开了通过免疫调节治疗妊娠并发症的方法。 还公开了能够在受试者中诱导抗炎免疫应答的益生菌组合物。 益生菌组合物可以包括一种或多种嗜热链球菌，罗伊氏乳杆菌，双歧双歧杆菌，嗜酸乳酸杆菌和干酪乳杆菌。
-
公开(公告)号：US20240131076A1
公开(公告)日：2024-04-25
申请号：US18493694
申请日：2023-10-23
IPC分类号： A61K35/28 , A61P25/08 , C12N5/0775
CPC分类号： A61K35/28 , A61P25/08 , C12N5/0662
摘要： Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit neuronal hyperactivation and/or reduce neuroinflammatory status of the patient
-
49.发明公开公开(公告)号：US20240091269A1
公开(公告)日：2024-03-21
申请号：US18470304
申请日：2023-09-19
摘要： The invention discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering from bipolar disorder.
-
50.发明公开公开(公告)号：US20230364148A1
公开(公告)日：2023-11-16
申请号：US18316084
申请日：2023-05-11
CPC分类号： A61K35/28 , A61K35/44 , A61K38/193 , A61P11/00
摘要： Disclosed are means, treatment methods, and compositions of matter useful for prevention and/or reversion of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cells and exosome thereof as a means of augmenting endogenous endothelial regeneration and/or endothelial regeneration stimulated by exogenous means. In some embodiments the invention provides administration of allogeneic mesenchymal stem cells together with autologous endothelial progenitor cells and/or mobilization of said autologous endothelial progenitor cells.
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.014 秒)
